Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Beijing Tiantan Hospital: Clinical Trials & FDA Approval Profile

Beijing Tiantan Hospital (Global / Institutional) sponsors 86 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 41 active protocols (17 recruiting now), 22 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)452 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Beijing Tiantan Hospital
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)86
Active Pipeline (Recruiting Now)41 (17)
Completed vs Stopped Early22 / 0 (0.0%)
Median Closed Actual Enrollment452 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Beijing Tiantan Hospital
Hospital Research SiteLocationShared Protocols
Beijing Tiantan Hospital, Capital Medical UniversityBeijing, Beijing Municipality28
Liaocheng People's hospitalLiaocheng, Shandong7
The First Hospital of Jilin UniversityChangchun, Jilin5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Beijing Tiantan Hospital
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06157502Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)Phase IIIRECRUITING
NCT04078737Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events IIPhase IIICOMPLETED
NCT05439356Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)Phase IIICOMPLETED
NCT06316570Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic StrokePhase IIICOMPLETED
NCT04797013Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-ⅡPhase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Beijing Tiantan Hospital Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI